BACKGROUND: Recommendations for diabetes prevention in patients with prediabetes include lifestyle modification and metformin. However, the significance of early weight loss and glucose measurements when monitoring response to these proven interventions is unknown. OBJECTIVE: To quantify the relationship between early measures of weight and glucose and subsequent diabetes in patients undergoing diabetes prevention interventions. DESIGN: Analysis of results from a randomized controlled trial in 27 academic medical centers in the United States. PARTICIPANTS/ INTERVENTIONS:3,041 adults with hyperglycemia randomized to lifestyle (n = 1,018), metformin (n = 1,036), or placebo (n = 987) with complete follow-up in The Diabetes Prevention Program. MAIN MEASURES: Independent variables were weight loss at 6 and 12 months; fasting glucose (FG) at 6 months; hemoglobin A1c (HbA1c) at 6 months; and post-load glucose at 12 months. The main outcome was time to diabetes diagnosis. KEY RESULTS: After 6 months, 604 participants developed diabetes in the lifestyle (n = 140), metformin (n = 206), and placebo (n = 258) arms over 2.7 years. In the lifestyle arm, 6-month weight loss predicted decreased diabetes risk in a graded fashion: adjusted HR (95 % CI) 0.65 (0.35-1.22), 0.62 (0.33-1.18), 0.46 (0.24-0.87), 0.34 (0.18-0.64), and 0.15 (0.07-0.30) for 0-<3 %, 3-<5 %, 5-<7 %, 7-<10 %, and ≥10 % weight loss, respectively (reference: weight gain). Attainment of optimal 6-month FG and HbA1c and 12-month post-load glucose predicted >60 % lower diabetes risk across arms. We found a significant interaction between 6-month weight loss and FG in the lifestyle arm (P = 0.038). CONCLUSION:Weight and glucose at 6 and 12 months strongly predict lower subsequent diabetes risk with a lifestyle intervention; lower FG predicts lower risk even with substantial weight loss. Early reduction in glycemia is a stronger predictor of future diabetes risk than weight loss for metformin. We offer the first evidence to guide clinicians in making interval management decisions for high-risk patients undertaking measures to prevent diabetes.
RCT Entities:
BACKGROUND: Recommendations for diabetes prevention in patients with prediabetes include lifestyle modification and metformin. However, the significance of early weight loss and glucose measurements when monitoring response to these proven interventions is unknown. OBJECTIVE: To quantify the relationship between early measures of weight and glucose and subsequent diabetes in patients undergoing diabetes prevention interventions. DESIGN: Analysis of results from a randomized controlled trial in 27 academic medical centers in the United States. PARTICIPANTS/ INTERVENTIONS: 3,041 adults with hyperglycemia randomized to lifestyle (n = 1,018), metformin (n = 1,036), or placebo (n = 987) with complete follow-up in The Diabetes Prevention Program. MAIN MEASURES: Independent variables were weight loss at 6 and 12 months; fasting glucose (FG) at 6 months; hemoglobin A1c (HbA1c) at 6 months; and post-load glucose at 12 months. The main outcome was time to diabetes diagnosis. KEY RESULTS: After 6 months, 604 participants developed diabetes in the lifestyle (n = 140), metformin (n = 206), and placebo (n = 258) arms over 2.7 years. In the lifestyle arm, 6-month weight loss predicted decreased diabetes risk in a graded fashion: adjusted HR (95 % CI) 0.65 (0.35-1.22), 0.62 (0.33-1.18), 0.46 (0.24-0.87), 0.34 (0.18-0.64), and 0.15 (0.07-0.30) for 0-<3 %, 3-<5 %, 5-<7 %, 7-<10 %, and ≥10 % weight loss, respectively (reference: weight gain). Attainment of optimal 6-month FG and HbA1c and 12-month post-load glucose predicted >60 % lower diabetes risk across arms. We found a significant interaction between 6-month weight loss and FG in the lifestyle arm (P = 0.038). CONCLUSION: Weight and glucose at 6 and 12 months strongly predict lower subsequent diabetes risk with a lifestyle intervention; lower FG predicts lower risk even with substantial weight loss. Early reduction in glycemia is a stronger predictor of future diabetes risk than weight loss for metformin. We offer the first evidence to guide clinicians in making interval management decisions for high-risk patients undertaking measures to prevent diabetes.
Authors: Richard F Hamman; Rena R Wing; Sharon L Edelstein; John M Lachin; George A Bray; Linda Delahanty; Mary Hoskin; Andrea M Kriska; Elizabeth J Mayer-Davis; Xavier Pi-Sunyer; Judith Regensteiner; Beth Venditti; Judith Wylie-Rosett Journal: Diabetes Care Date: 2006-09 Impact factor: 19.112
Authors: J Tuomilehto; J Lindström; J G Eriksson; T T Valle; H Hämäläinen; P Ilanne-Parikka; S Keinänen-Kiukaanniemi; M Laakso; A Louheranta; M Rastas; V Salminen; M Uusitupa Journal: N Engl J Med Date: 2001-05-03 Impact factor: 91.245
Authors: William C Knowler; Elizabeth Barrett-Connor; Sarah E Fowler; Richard F Hamman; John M Lachin; Elizabeth A Walker; David M Nathan Journal: N Engl J Med Date: 2002-02-07 Impact factor: 91.245
Authors: Rena R Wing; Richard F Hamman; George A Bray; Linda Delahanty; Sharon L Edelstein; James O Hill; Edward S Horton; Mary A Hoskin; Andrea Kriska; John Lachin; Elizabeth J Mayer-Davis; Xavier Pi-Sunyer; Judith G Regensteiner; Beth Venditti; Judith Wylie-Rosett Journal: Obes Res Date: 2004-09
Authors: David B Sarwer; Amy von Sydow Green; Marion L Vetter; Thomas A Wadden Journal: Curr Opin Endocrinol Diabetes Obes Date: 2009-10 Impact factor: 3.243
Authors: William C Knowler; Sarah E Fowler; Richard F Hamman; Costas A Christophi; Heather J Hoffman; Anne T Brenneman; Janet O Brown-Friday; Ronald Goldberg; Elizabeth Venditti; David M Nathan Journal: Lancet Date: 2009-10-29 Impact factor: 79.321
Authors: John M Lachin; Costas A Christophi; Sharon L Edelstein; David A Ehrmann; Richard F Hamman; Steven E Kahn; William C Knowler; David M Nathan Journal: Diabetes Date: 2007-04 Impact factor: 9.461
Authors: Leigh Perreault; Steven E Kahn; Costas A Christophi; William C Knowler; Richard F Hamman Journal: Diabetes Care Date: 2009-07-08 Impact factor: 19.112
Authors: Katherine A Pratte; Ann Johnson; Janette Beals; Ann Bullock; Spero M Manson; Luohua Jiang Journal: Diabetes Care Date: 2019-06-08 Impact factor: 19.112
Authors: Mary A Hoskin; George A Bray; Kathy Hattaway; Prajakta A Khare-Ranade; Jeremy Pomeroy; Linda N Semler; Valarie A Weinzierl; Judith Wylie-Rosett Journal: Curr Nutr Rep Date: 2014-12-01
Authors: Eva Tseng; Raquel C Greer; Paul O'Rourke; Hsin-Chieh Yeh; Maura M McGuire; Ann L Albright; Jill A Marsteller; Jeanne M Clark; Nisa M Maruthur Journal: J Gen Intern Med Date: 2019-09-09 Impact factor: 5.128
Authors: James A Dunbar; Andrea L Hernan; Edward D Janus; Erkki Vartiainen; Tiina Laatikainen; Vincent L Versace; John Reynolds; James D Best; Timothy C Skinner; Sharleen L O'Reilly; Kevin P Mc Namara; Elizabeth Stewart; Michael Coates; Catherine M Bennett; Rob Carter Journal: BMJ Open Diabetes Res Care Date: 2015-10-01
Authors: Kellie R Weinhold; Carla K Miller; David G Marrero; Haikady N Nagaraja; Brian C Focht; Gregg M Gascon Journal: Prev Chronic Dis Date: 2015-11-25 Impact factor: 2.830